
Quarterly report 2025-Q2
added 07-28-2025
Ekso Bionics Holdings Financial Statements 2011-2026 | EKSO
Annual Financial Statements Ekso Bionics Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
9.68 M | 29 M | 19.7 M | 32.3 M | 72.1 M | 28 M | 107 M | 55.2 M | 74.1 M | 117 M | 142 M | 804 M | - | - |
Shares |
20.2 M | 13.9 M | 13 M | 12.2 M | 8.24 M | 4.79 M | 4.08 M | 2.37 M | 1.21 M | 1.26 M | 966 K | 3.14 M | - | - |
Historical Prices |
0.48 | 2.09 | 1.52 | 2.65 | 6.13 | 5.87 | 18.6 | 31.9 | 59.7 | 107 | 143 | - | - | - |
Net Income |
-11.3 M | -15.2 M | -15.1 M | -9.76 M | -15.8 M | -12.1 M | -27 M | -29.1 M | -23.5 M | -19.6 M | -33.8 M | -12.3 K | - | - |
Revenue |
17.9 M | 18.3 M | 12.9 M | 11.2 M | 8.88 M | 13.9 M | 11.3 M | 7.35 M | 14.2 M | 8.66 M | 5.33 M | - | - | - |
Cost of Revenue |
8.41 M | 9.2 M | 6.7 M | 4.5 M | 3.81 M | 7.15 M | 7.02 M | 5.28 M | 11.3 M | 7.48 M | 3.77 M | 2.72 M | 2.34 M | - |
Gross Profit |
9.51 M | 9.08 M | 6.21 M | 6.75 M | 5.07 M | 6.76 M | 4.31 M | 2.07 M | 2.95 M | 1.18 M | 1.56 M | - | - | - |
Operating Income |
-10.5 M | -15.1 M | -15.6 M | -13.8 M | -13.3 M | -16.6 M | -27 M | -31.6 M | -27.6 M | -21.6 M | -16.8 M | -10.3 M | -14.2 M | - |
Interest Expense |
-1 K | -63 K | 156 K | 113 K | 139 K | 384 K | 600 K | 648 K | 16 K | 13 K | 435 K | 1.73 M | 736 K | - |
EBITDA |
-8.85 M | -13.4 M | -14.7 M | -12.8 M | -12.2 M | -15.9 M | -25.6 M | -29.6 M | -25.9 M | -20.6 M | -16 M | -10.9 K | - | - |
Operating Expenses |
20 M | 24.2 M | 21.8 M | 20.6 M | 17.9 M | 23.4 M | 31.4 M | 33.4 M | 30.7 M | 22.7 M | 18.4 M | 11.4 K | - | - |
General and Administrative Expenses |
8.79 M | 10.7 M | 11 M | 10.7 M | 7.7 M | 7.41 M | 11.7 M | 10.7 M | 10.9 M | 7 M | 7.4 M | 10.9 K | - | - |
All numbers in USD currency
Quarterly Income Statement Ekso Bionics Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
2.18 M | 25.4 M | 1.48 M | 20.3 M | 1.22 M | 17.4 M | 14.8 M | 14.1 M | 13.6 M | 13.3 M | 13.2 M | 13.1 M | 12.9 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 10.8 M | 8.35 M | 8.24 M | 6.26 M | 5.8 M | 5.8 M | 5 M | 4.71 M | 4.34 M | 63 M | 61.4 M | 60.6 M | 60.1 M | 59.9 M | 34.7 M | 25.5 M | 21.9 M | 21.9 M | 19 M | 16.2 M | 15.4 M | 15 M | 14.6 M | 102 M | 102 M | 102 M | 78.5 M | 78.5 M | 67.1 M | 22 M | 21.1 M | 21.1 M | 20.6 M | 19.1 M | 17.9 M | 5 M | 6.35 M | - | - | - | - |
Net Income |
-2.71 M | -2.89 M | - | -2.07 M | -2.42 M | -3.43 M | - | -3.36 M | -4.23 M | -4.39 M | - | -4.3 M | -2.98 M | -4.62 M | - | -1.96 M | -1.27 M | -3.67 M | - | 2.45 M | -11.8 M | -2.53 M | - | 206 K | -3.07 M | -6.55 M | - | -6.98 M | -7.98 M | -7.9 M | -8.98 M | -6.34 M | -5.51 M | -8.3 M | -5.58 M | -8.48 M | -5.76 M | -3.65 M | -4.64 M | -5.18 M | -5.64 M | -4.12 M | -20.2 M | 12 M | 56.1 M | -81.8 M | -6.08 K | -11.9 M | -11.9 M | -11.9 M | -1.78 K | -7.92 K | -1.25 K | -4.66 K | - | - | - | - |
Revenue |
2.06 M | 3.38 M | - | 4.13 M | 4.95 M | 3.76 M | - | 4.61 M | 4.7 M | 4.12 M | - | 3.33 M | 3.46 M | 2.57 M | - | 3.05 M | 2.21 M | 1.91 M | - | 2.9 M | 66 K | 1.47 M | - | - | - | 3.62 M | - | 2.55 M | 2.97 M | 2.52 M | 2.45 M | 1.6 M | 1.87 M | 1.44 M | 2.59 M | 1.6 M | 1.55 M | 8.49 M | 1.94 M | 2.92 M | 2.11 M | 1.69 M | 1.48 M | 1.59 M | 1.2 M | 1.06 M | - | 834 K | 984 K | 696 K | - | - | - | - | - | - | - | - |
Cost of Revenue |
1.24 M | 1.57 M | - | 1.92 M | 2.31 M | 1.8 M | - | 2.15 M | 2.45 M | 2.12 M | - | 1.64 M | 1.82 M | 1.36 M | - | 1.24 M | 919 K | 675 K | - | 1.08 M | 1 M | 831 K | - | 1.57 M | 1.7 M | 2.02 M | - | 1.47 M | 2 M | 1.75 M | - | 1.05 M | 1.47 M | 1.08 M | - | 1.19 M | 1.35 M | 6.99 M | - | 2.45 M | 1.61 M | 1.29 M | - | 1.11 M | 1.15 M | 582 K | - | 533 K | 681 K | 580 K | - | - | - | - | - | - | - | - |
Gross Profit |
819 K | 1.81 M | - | 2.21 M | 2.64 M | 1.95 M | - | 2.46 M | 2.25 M | 2 M | - | 1.69 M | 1.64 M | 1.21 M | - | 1.81 M | 1.29 M | 1.24 M | - | 1.81 M | 1.26 M | 637 K | - | 1.75 M | 1.56 M | 1.6 M | - | 1.08 M | 967 K | 767 K | 777 K | 544 K | 396 K | 352 K | 843 K | 403 K | 203 K | 1.5 M | -194 K | 468 K | 502 K | 403 K | 554 K | 480 K | 45 K | 480 K | - | 301 K | 303 K | 116 K | - | - | - | - | - | - | - | - |
Operating Income |
-3.98 M | -3.44 M | - | -2.64 M | -2.34 M | -3.26 M | - | -2.93 M | -4.28 M | -4.45 M | - | -3.65 M | -3.23 M | -4.24 M | - | -2.79 M | -3.35 M | -3.14 M | - | -2.42 M | -3.09 M | -4.78 M | - | -3.79 M | -5.1 M | -4.91 M | - | -6.09 M | -7.18 M | -8.61 M | - | -7.07 M | -8.46 M | -8.14 M | - | -6.87 M | -7.4 M | -6.64 M | - | -5.18 M | -5.64 M | -4.09 M | - | -3.73 M | -4.31 M | -3.89 M | -6.08 K | -1.67 M | -2.71 M | -3.15 M | -1.78 K | -7.92 K | -1.25 K | -4.66 K | - | - | - | - |
Interest Expense |
-8 K | -6 K | - | -2 K | - | 57 K | - | 3 K | -30 K | 112 K | - | 34 K | 29 K | 27 K | - | 24 K | 27 K | 26 K | - | 23 K | 38 K | 52 K | - | 88 K | 107 K | 121 K | - | 145 K | 160 K | 163 K | - | 165 K | 198 K | 119 K | - | -1.61 M | 1.63 M | 2.99 M | - | 4 K | 3 K | 3 K | - | 3 K | 3 K | 427 K | - | 170 K | 674 K | 639 K | - | - | - | - | - | - | - | - |
EBITDA |
- | -3.06 M | - | - | - | -2.85 M | - | - | - | -4.03 M | - | -3.02 M | -3.23 M | -4.01 M | - | -2.01 M | -3.35 M | -3.14 M | - | -1.96 M | -3.07 M | -4.77 M | - | -3.73 M | -5.04 M | -4.88 M | - | -5.98 M | -7.1 M | -8.57 M | - | -5.75 M | -7.59 M | -7.7 M | - | -5.48 M | -6.49 M | -6.2 M | - | -4.53 M | -5.22 M | -3.89 M | - | -3.2 M | -3.98 M | -3.73 M | -6.08 K | -1.33 M | -2.48 M | -3.04 M | -1.78 K | -7.92 K | -1.25 K | -4.66 K | - | - | - | - |
Operating Expenses |
4.79 M | 5.25 M | - | 4.85 M | 4.97 M | 5.21 M | - | 5.39 M | 6.54 M | 6.45 M | - | 5.34 M | 4.87 M | 5.45 M | - | 4.6 M | 4.64 M | 4.37 M | - | 4.23 M | 4.35 M | 5.42 M | - | 5.54 M | 6.66 M | 6.51 M | - | 7.18 M | 8.15 M | 9.38 M | - | 7.61 M | 8.86 M | 8.49 M | - | 7.27 M | 7.6 M | 8.14 M | - | 5.65 M | 6.14 M | 4.5 M | - | 4.21 M | 4.36 M | 4.37 M | 6.08 K | 1.97 M | 3.01 M | 3.27 M | 1.78 K | 7.92 K | 1.25 K | 4.66 K | - | - | - | - |
General and Administrative Expenses |
2.25 M | 2.55 M | - | 2.31 M | 2.01 M | 2.25 M | - | 2.18 M | 2.79 M | 3.21 M | - | 2.71 M | 2.16 M | 2.9 M | - | 2.29 M | 2.14 M | 1.98 M | - | 1.71 M | 1.94 M | 2.19 M | - | 1.57 M | 2.12 M | 2.32 M | - | 2.78 M | 2.83 M | 3.74 M | - | 2.41 M | 2.48 M | 2.54 M | - | 2.32 M | 2.46 M | 3.49 M | - | 1.56 M | 1.87 M | 1.66 M | - | 1.47 M | 1.81 M | 2.07 M | 4.17 K | 752 K | 969 K | 1.13 M | 50 | 88 | 25 | 157 | - | - | - | - |
All numbers in USD currency
Main types of financial statements Ekso Bionics Holdings EKSOFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Ekso Bionics Holdings plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Baxter International
BAX
|
$ 20.38 | -0.8 % | $ 10.4 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 203.39 | -0.93 % | $ 58.5 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Harvard Bioscience
HBIO
|
$ 0.67 | -2.84 % | $ 28.4 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
LeMaitre Vascular
LMAT
|
$ 83.44 | -0.09 % | $ 1.87 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Merit Medical Systems
MMSI
|
$ 91.18 | -2.0 % | $ 5.31 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
$ 80.74 | -1.34 % | $ 40.4 B | ||
|
iRhythm Technologies
IRTC
|
$ 187.58 | 1.41 % | $ 5.85 B | ||
|
OraSure Technologies
OSUR
|
$ 2.5 | 0.6 % | $ 186 M | ||
|
AtriCure
ATRC
|
$ 41.29 | -0.36 % | $ 1.94 B | ||
|
Repro Med Systems
KRMD
|
$ 5.69 | 1.79 % | $ 259 M | ||
|
electroCore
ECOR
|
$ 4.81 | -1.26 % | $ 26.5 K | ||
|
ICU Medical
ICUI
|
$ 150.56 | -0.15 % | $ 3.67 B | ||
|
AngioDynamics
ANGO
|
$ 11.02 | -3.67 % | $ 450 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
$ 83.83 | -0.58 % | $ 16.7 B | ||
|
STERIS plc
STE
|
$ 259.25 | -0.25 % | $ 25.6 B | ||
|
Glaukos Corporation
GKOS
|
$ 113.49 | 0.99 % | $ 5.5 B | ||
|
Haemonetics Corporation
HAE
|
$ 83.15 | 0.48 % | $ 4.18 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.93 | 1.82 % | $ 184 M | ||
|
Nephros
NEPH
|
$ 5.28 | -2.4 % | $ 54.8 M | ||
|
Masimo Corporation
MASI
|
$ 137.22 | 0.45 % | $ 7.31 B | ||
|
Predictive Oncology
POAI
|
$ 6.37 | -0.78 % | $ 34.7 M | ||
|
Intuitive Surgical
ISRG
|
$ 592.66 | -0.03 % | $ 211 B | ||
|
Utah Medical Products
UTMD
|
$ 57.83 | 1.03 % | $ 210 M | ||
|
Microbot Medical
MBOT
|
$ 2.1 | -1.41 % | $ 21.4 M | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | -2.42 % | $ 22.3 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 22.84 | -1.64 % | $ 3.93 B | ||
|
Stereotaxis
STXS
|
$ 2.54 | -0.59 % | $ 205 M | ||
|
Pro-Dex
PDEX
|
$ 40.18 | -1.9 % | $ 132 M | ||
|
Pulse Biosciences
PLSE
|
$ 15.15 | 3.25 % | $ 728 M | ||
|
Repligen Corporation
RGEN
|
$ 168.5 | -2.18 % | $ 9.39 M | ||
|
ResMed
RMD
|
$ 248.48 | -0.28 % | $ 36.3 B | ||
|
BioLife Solutions
BLFS
|
$ 25.52 | -3.15 % | $ 1.18 B | ||
|
Retractable Technologies
RVP
|
$ 0.77 | 0.92 % | $ 23.1 M | ||
|
STAAR Surgical Company
STAA
|
$ 22.1 | -0.85 % | $ 1.09 B | ||
|
Teleflex Incorporated
TFX
|
$ 126.75 | 1.6 % | $ 5.94 B | ||
|
West Pharmaceutical Services
WST
|
$ 279.92 | -0.3 % | $ 20.4 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 12.38 | 0.04 % | $ 2.52 B |